This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2026 ,inter alia, to consider and approve Notice of Board meeting
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivimed Labs has informed the stock exchanges that its Board of Directors will meet on Friday, 13 March 2026, at Hyderabad. The main agenda is to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 (Q3 FY26). The notice also includes the usual 'any other items with the permission of the Chair' clause, meaning additional matters could be tabled. The filing is made under SEBI Listing Regulations and is a routine pre-results announcement. No actual financial numbers have been shared in this filing — those will come after the board meeting.
Routine regulatory disclosure with no immediate impact on the stock. Investors should watch for the actual Q3 results announcement on or after 13 March 2026, which could move the stock depending on performance versus expectations.
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹15.99 Cr | ₹36.51 Cr | −56.2% |
| Operating profit | −₹16.55 Cr | −₹6.04 Cr | loss widened |
| Profit after tax | −₹16.55 Cr | −₹5.98 Cr | loss widened |
| EBITDA margin | -68.3% | 2.9% | −71.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.